New pancreatic cancer drug costs $480,000 a year — the new normal for cancer treatments

Revolution Medicines has launched Rasonque, a new pancreatic cancer treatment priced at $480,000 per year. The drug exemplifies the dramatic inflation in cancer drug prices seen over the past two decades. Experts warn that such extreme pricing is becoming the new normal in oncology.